Pharmacists’ generic drug substitution obligations.

<p>Green = mandatory for all dispensings; blue = mandatory for dispensings paid for by government-sponsored insurance plans; and white = permissive.</p

Patient consent for generic drug substitution.

<p>Red = required, and white = not required.</p

Representative Quotations in Key Subject Areas.

<p>Representative Quotations in Key Subject Areas.</p

Approvals of New Orphan-Designated Drugs Indicated for Biomarker-Defined Subsets of More Common Diseases, 2009–2015

<p>Approvals of New Orphan-Designated Drugs Indicated for Biomarker-Defined Subsets of More Common Diseases, 2009–2015</p

Studies assessing and/or comparing US and EU systems for approval and post-market surveillance of medical devices.

<p>Studies assessing and/or comparing US and EU systems for approval and post-market surveillance of medical devices.</p

PRISMA schematic of systematic review search process.

<p>PRISMA schematic of systematic review search process.</p

Pharmaceutical fraud cases related to off-label marketing, January 1996–October 2010.

<p>Pharmaceutical fraud cases related to off-label marketing, January 1996–October 2010.</p

Approved follow-on biologics in the EU.

<p>Approved follow-on biologics in the EU.</p

Authors’ evaluation of physician-centered strategies to promote generic drug and follow-on biologic prescribing

<p>^* Pending further evidence.</p><p><a href="http://www.plosmedicine.org/article/info:doi/10.1371/journal.pmed.1001802#t002fn001" target="_blank">^*</a></p

Examples of adequate and inadequate disclosure.

<p>Examples of adequate and inadequate disclosure.</p